Date |
Acquired company |
Acquiring company |
Amount |
Related |
2018-12-03 |
TxCell (France) |
Sangamo Therapeutics (USA - CA) |
€ 72 million |
Cell therapy - CAR-T - Immunological diseases |
2018-10-18 |
Endocyte (USA - IN) |
Novartis (Switzerland) |
$ 2.1 billion |
Cancer - Oncology |
2018-10-09 |
Vector Neurosciences (UK) |
MeiraGTx (USA - NY) |
|
Neurodegenerative diseases - CNS diseases |
2018-10-01 |
Sanofi’s inhalation contract manufacturing business |
Recipharm (Sweden) |
undisclosed |
Technology - Services |
2018-09-26 |
Syntimmune (USA - MA) |
Alexion Pharmaceuticals (USA -MA) |
up to $1.2 billion |
Autoimmune diseases |
2018-09-20 |
Celenex |
Amicus Therapeutics (USA - NJ) |
$100 million in an upfront cash payment and up to $15 million in development milestones and $262 million in BLA/MAA submission and approval milestones |
Gene Therapy - Rare diseases - CNS diseases |
2018-09-14 |
Bonti (USA - CA) |
Allergan (Ireland) |
$195 million and additional potential commercial milestone payments, subject to certain adjustments and other customary closing conditions |
aesthetic medicine |
2018-09-13 |
Viratherapeutics (Austria) |
Boehringer Ingelheim (Germany) |
€210 million |
Cancer - Oncology |
2018-09-06 |
Advanced Bioprocessing Business from BectonDickinson (USA - NJ) |
Thermo Fisher Scientific (USA - MA) |
|
Technology - Services |
2018-08-31 |
Galderma R&D site in Sophia-Antipolis - Nestlé Skin Health (Switzerland) |
Nuvisan (Germany) |
|
CRO - analytical services |
2018-07-19 |
Agilis Biotherapeutics (USA - MA) |
PTC Therapeutics (USA - NJ) |
up to $260 million and success-based milestones |
Rare diseases - CNS Diseases - Gene therapy
|
2018-06-16 |
Interactive Biosoftware (Frane) |
Sophia Genetics (France - Switzerland) |
undisclosed |
|
2018-05-15 |
Avexis (USA - IL) |
Novartis (Switzerland) |
$ 8.7 billion |
Gene therapy - Neurodegenerative diseases - CNS diseases |
2018-05-14 |
AurKa Pharma (Canada) |
Eli Lilly (USA - IN) |
up to $575 million |
Cancer - Oncology |
2018-05-10 |
ARMO BioSciences (USA - CA) |
Eli Lilly (USA - IN) |
$1.6 billion |
Cancer - Oncology |
2018-04-16 |
Shire's oncology business (UK-USA) |
Servier (France) |
$2.4 billion (€1.94 billion) |
|
2018-02-21 |
Viralytics (Australia) |
Merck&Co (USA - NJ) |
$394 million |
Cancer - Oncology |
2018-02-20 |
Clinical Assistance Programs (CAP) (USA - MA) |
Alira Health (France - Germany - Italy - Spain - USA) |
undisclosed |
Technology - Services |
2018-02-01 |
Advanced Accelerator Applications (France) |
Novartis (Switzerland) |
$3.9 billion |
Cancer - Oncology |
2018-01-29 |
Ablynx (Belgium) |
Sanofi (France) |
€3.9 billion |
Hematological diseases - Inflammatory diseases |